| Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation A Saito, T Irie, R Suzuki, T Maemura, H Nasser, K Uriu, Y Kosugi, ... Nature 602 (7896), 300-306, 2022 | 586* | 2022 |
| SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity C Motozono, M Toyoda, J Zahradnik, A Saito, H Nasser, TS Tan, I Ngare, ... Cell host & microbe 29 (7), 1124-1136. e11, 2021 | 539* | 2021 |
| Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant R Suzuki, D Yamasoba, I Kimura, L Wang, M Kishimoto, J Ito, Y Morioka, ... Nature 603 (7902), 700-705, 2022 | 523 | 2022 |
| Virological characteristics of the SARS-CoV-2 Omicron BA. 2 spike D Yamasoba, I Kimura, H Nasser, Y Morioka, N Nao, J Ito, K Uriu, ... Cell 185 (12), 2103-2115. e19, 2022 | 341* | 2022 |
| Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5 I Kimura, D Yamasoba, T Tamura, N Nao, Y Oda, S Mitoma, J Ito, ... Cell 185 (21), 3992-4007, 2022 | 210 | 2022 |
| Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants T Tamura, J Ito, K Uriu, J Zahradnik, I Kida, Y Anraku, H Nasser, M Shofa, ... Nature communications 14 (1), 2800, 2023 | 176 | 2023 |
| Potential role of the formation of tunneling nanotubes in HIV-1 spread in macrophages M Hashimoto, F Bhuyan, M Hiyoshi, O Noyori, H Nasser, M Miyazaki, ... The Journal of Immunology 196 (4), 1832-1841, 2016 | 119 | 2016 |
| Virological characteristics of the SARS-CoV-2 Omicron BA. 2.75 variant A Saito, T Tamura, J Zahradnik, S Deguchi, K Tabata, Y Anraku, I Kimura, ... Cell host & microbe 30 (11), 1540-1555. e15, 2022 | 106 | 2022 |
| Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ. 1.1 variant J Ito, R Suzuki, K Uriu, Y Itakura, J Zahradnik, KT Kimura, S Deguchi, ... Nature communications 14 (1), 2671, 2023 | 77 | 2023 |
| Virological characteristics of the novel SARS-CoV-2 Omicron variants including BA. 2.12. 1 I Kimura, D Yamasoba, T Tamura, N Nao, Y Oda, S Mitoma, J Ito, ... BA 4, 2022.05, 2022 | 48 | 2022 |
| Lethal interactions of SARS-CoV-2 with graphene oxide: Implications for COVID-19 treatment M Fukuda, MS Islam, R Shimizu, H Nasser, NN Rabin, Y Takahashi, ... ACS Applied Nano Materials 4 (11), 11881-11887, 2021 | 39 | 2021 |
| M-CSF inhibits anti–HIV-1 activity of IL-32, but they enhance M2-like phenotypes of macrophages A Osman, F Bhuyan, M Hashimoto, H Nasser, T Maekawa, S Suzu The Journal of Immunology 192 (11), 5083-5089, 2014 | 33 | 2014 |
| The Genotype to Phenotype Japan (G2P-Japan) Consortium D Yamasoba, I Kimura, H Nasser, Y Morioka, N Nao, J Ito, K Uriu, ... Neutralization sensitivity of Omicron BA 2, 2023 | 32 | 2023 |
| Virological characteristics of the SARS-CoV-2 BA. 2.86 variant T Tamura, K Mizuma, H Nasser, S Deguchi, M Padilla-Blanco, Y Oda, ... Cell Host & Microbe 32 (2), 170-180. e12, 2024 | 25 | 2024 |
| Apolipoprotein E is an HIV-1-inducible inhibitor of viral production and infectivity in macrophages R Siddiqui, S Suzu, M Ueno, H Nasser, R Koba, F Bhuyan, O Noyori, ... PLoS pathogens 14 (11), e1007372, 2018 | 25 | 2018 |
| Establishment of bone marrow-derived M-CSF receptor-dependent self-renewing macrophages H Nasser, P Adhikary, A Abdel-Daim, O Noyori, J Panaampon, R Kariya, ... Cell death discovery 6 (1), 63, 2020 | 24 | 2020 |
| Fibrocytes differ from macrophages but can be infected with HIV-1 M Hashimoto, H Nasser, F Bhuyan, N Kuse, Y Satou, S Harada, ... The Journal of Immunology 195 (9), 4341-4350, 2015 | 19 | 2015 |
| Macropinocytosis and TAK1 mediate anti-inflammatory to pro-inflammatory macrophage differentiation by HIV-1 Nef M Hashimoto, H Nasser, T Chihara, S Suzu Cell Death & Disease 5 (5), e1267-e1267, 2014 | 19 | 2014 |
| M-Sec facilitates intercellular transmission of HIV-1 through multiple mechanisms S Lotfi, H Nasser, O Noyori, M Hiyoshi, H Takeuchi, Y Koyanagi, S Suzu Retrovirology 17, 1-11, 2020 | 17 | 2020 |
| Expression of IL‐34 correlates with macrophage infiltration and prognosis of diffuse large B‐cell lymphoma O Noyori, Y Komohara, H Nasser, M Hiyoshi, C Ma, C Pan, J Carreras, ... Clinical & translational immunology 8 (8), e1074, 2019 | 16 | 2019 |
